Edition:
United States

Theraclion SA (ALTHER.PA)

ALTHER.PA on Paris Stock Exchange

5.10EUR
18 Aug 2017
Change (% chg)

€-0.01 (-0.20%)
Prev Close
€5.11
Open
€5.10
Day's High
€5.10
Day's Low
€5.10
Volume
20
Avg. Vol
7,993
52-wk High
€6.81
52-wk Low
€4.67

Latest Key Developments (Source: Significant Developments)

Theraclion H1 revenue eur 561,000
Monday, 10 Jul 2017 12:00pm EDT 

July 10 (Reuters) - THERACLION SA ::H1 REVENUE EUR 561,000 VERSUS EUR 463,000 MILLION YEAR AGO.OBTAINED NEW FUNDING UNDER ITS TUCE PROJECT IN COLLABORATION WITH SUPERSONIC IMAGINE.  Full Article

Theraclion announces FDA authorization to start US trial for immunotherapy and echotherapy combination on breast cancer
Monday, 26 Jun 2017 12:00pm EDT 

June 26 (Reuters) - THERACLION SA ::THERACLION ANNOUNCES FDA AUTHORIZATION TO START U.S. TRIAL FOR IMMUNOTHERAPY AND ECHOTHERAPY COMBINATION ON BREAST CANCER.  Full Article

Theraclion and Inner Mongolia Furui Medical Science Co. sign joint venture in China
Monday, 24 Apr 2017 12:00pm EDT 

April 24 (Reuters) - Theraclion SA ::And Inner Mongolia Furui Medical Science Co., Ltd sign joint venture in China.Creates Chinese company in which co owns majority stake.Will own 56 pct of Theraclion China Co., Ltd and Inner Mongolia Furui Medical Science Co., Ltd 44 pct.  Full Article

Theraclion reports positive long-term Echopulse results in breast fibroadenoma
Thursday, 6 Apr 2017 12:00pm EDT 

Theraclion SA : Theraclion reports positive long-term Echopulse results in breast fibroadenoma . Mean volume reduction at 24 months: 77 pct (small volumes fibroadenoma: treatment in single session); 90 pct (larger volumes: treatment in 2 sessions) . Volume reduction is maintained at 24 months following treatment with no evidence of recurrence .Treatment is safe and well-tolerated by patients.  Full Article

Theraclion FY net loss stable at 6.8 million euros
Monday, 27 Mar 2017 12:00pm EDT 

Theraclion SA : Theraclion presents its 2016 consolidated annual results . FY revenue 1.9 million euros ($2.1 million) versus 1.5 million euros year ago . FY operating loss of 7.8 million euros versus loss of 7.2 million euros year ago . FY net loss stable at 6.8 million euros (versus 6.4 million euros year ago) . At 31 december 2016, theraclion had available cash of eur 6,990,000 versus eur 3,753,000 at 31 december 2015 ."In 2017 we anticipate further growth in sales, in our installed base and in treatments, which already advanced strongly in 2016" - CEO.  Full Article

Theraclion 2016 sales of 1.9 million euros, up 8 pct
Friday, 3 Feb 2017 02:00am EST 

Theraclion SA : Growth continues in 2016 . 2016 sales of 1.9 million euros ($2.0 million), up 8 percent .In 2016 291 routine clinical treatments, up 300 percent compared to 2015.  Full Article

Theraclion signs two commercial agreements in Frankfurt for Echopulse systems
Monday, 9 Jan 2017 12:30pm EST 

Theraclion SA : Signs two commercial agreements in Frankfurt; first city with two Echopulse systems available for thyroid nodules .Biggest German insurer covers Echotherapy procedure.  Full Article

First acquisition of Theraclion's Echopulse in Switzerland
Thursday, 8 Dec 2016 05:40am EST 

Theraclion SA :Ente Ospedaliero Cantonale, Swiss group of centers of excellence, exercises option to buy Theraclion's echotherapy system.  Full Article

Theraclion launches 9.63 million euro capital increase
Monday, 25 Jul 2016 02:10am EDT 

Theraclion SA : Announced on Saturday it launches capital increase of 9.63 million euros ($10.57 million) with preferential subscription rights . Subscription ratio: 1 new share for every 3 existing shares . Subscription price: 5.98 euros per share . Subscription period: July 26 to August 5, 2016 .Existing investors and other shareholders of the Company have committed to subscribe for the capital increase for about 71.7 pct of the shares offered.  Full Article

Theraclion H1 revenue jumps 1,119 pct to 463,000 euros
Friday, 8 Jul 2016 02:00am EDT 

Theraclion SA : H1 revenue EUR 463,000 ($512,772.50) versus EUR 38,000 year ago .Says is actively looking for a future strategic partner to access the Chinese market, what could result in a creation of a joint venture.  Full Article

BRIEF-Theraclion announces expansion of echotherapy reimbursement coverage in Germany

* THERACLION ANNOUNCES EXPANSION OF ECHOTHERAPY REIMBURSEMENT COVERAGE TO 14 MILLION LIVES IN GERMANY Source text for Eikon: Further company coverage: (Gdynia Newsroom)